Trinity Biotech Announces Q3 2024 Financial Results

Stock Information for Trinity Biotech plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Trinity Biotech plc

Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances
Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation
Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test
Trinity Biotech Welcomes Perceptive Advisor's Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
Trinity Biotech Appoints Paul Tivnan as Non-Executive Director
Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara(TM) Preeclampsia Testing Service

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.